Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study-Reference-Cited by-同舟云学术

Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

Published:2024-01 Issue: Volume:196 Page:113420
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

García-Sáenz José Angel,Marmé Frederik^ORCID,Untch Michael,Bonnefoi Hervé,Kim Sung-Bae,Bear Harry,Mc Carthy Nicole,Gelmon Karen,Martin Miguel,Kelly Catherine M.,Reimer Toralf^ORCID,Toi Masakazu,Law Ernest,Bhattacharyya Helen,Gnant Michael^ORCID,Makris Andreas,Seiler Sabine^ORCID,Burchardi Nicole,Nekljudova Valentina^ORCID,Loibl Sibylle^ORCID,Rugo Hope S.

Funder

Pfizer Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017

2. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020

3. Overall survival with palbociclib and fulvestrant in women with HR+/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study;Cristofanilli;Clin Cancer Res,2022

4. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival;Slamon;Ann Oncol,2021

5. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial;Sledge;JAMA Oncol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis;BMC Cancer;2024-08-21